JPLA
SRNE

Joseph P. Lucia & Associates’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Joseph P. Lucia & Associates’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-35
Closed – – 482
2020
Q2 		$0 Buy
+35
New +$134 ﹤0.01% 513

Other funds holding SRNE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Joseph P. Lucia & Associates's SRNE Position: Q3 2020 in Review

Joseph P. Lucia & Associates sold out of Sorrento Therapeutics, Inc. (SRNE) in Q3 2020, closing a stake of 35 shares.

Joseph P. Lucia & Associates first reported a position in SRNE in Q2 2020 and held it in 1 quarter. The position peaked at $0 in Q2 2020. 209 funds tracked by Wall St. Rank hold SRNE as of Q3 2020.

  • Joseph P. Lucia & Associates reported no remaining Sorrento Therapeutics, Inc. position as of Q3 2020 after selling out during the quarter.
  • Joseph P. Lucia & Associates sold 35 Sorrento Therapeutics, Inc. shares in Q3 2020.
  • Joseph P. Lucia & Associates first reported a position in Sorrento Therapeutics, Inc. in Q2 2020 and held it in 1 quarter.
  • Joseph P. Lucia & Associates's Sorrento Therapeutics, Inc. position peaked at $0 in Q2 2020.
  • 209 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q3 2020.

Based on Joseph P. Lucia & Associates's 13F filing for Q3 2020, filed 20 Oct 2020.